Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1989 Jun;27(3-4):274-6.
doi: 10.1007/BF01972795.

Effects of prostaglandins and cAMP levels on monocyte IL-1 production

Affiliations

Effects of prostaglandins and cAMP levels on monocyte IL-1 production

S Kassis et al. Agents Actions. 1989 Jun.

Abstract

The effects of prostaglandin E2 (PGE2), as well as other cAMP-elevating agents, on the in vitro production of interleukin-1 (IL-1) by human monocytes (HM) were examined. Exposure to E. coli lipopolysacharide (LPS) resulted in a dose- and time-dependent increase of IL-1 activity in monocytes culture supernatants. Maximal levels of secreted IL-1 in response to 10 ng LPS/ml were obtained at 18 h. PGE1, PGE2, cholera toxin (CT) and the phosphodiesterase inhibitor, isobutylmethylxanthin (IBMX), when added with LPS, resulted in a dose-dependent increase in cellular cAMP and in secreted IL-1. Maximal levels of secreted IL-1 were 2.5-5.0-fold over LPS alone. When CT or PGE2 was added with IBMX a further increase was observed. These agents exhibited marginal effect on cell-associated IL-1. Maximum cAMP levels was achieved at 10 min in response to either PGE1 or PGE2 and returned to near basal levels after 18 h. While PGE1 elevated cAMP to a larger extent than PGE2 (58- vs. 30-fold) the latter resulted in a higher levels of secreted IL-1. Elevated cAMP persisted throughout the entire culture period in response to CT (4-6-fold) or IBMX (7-fold). Thus, we conclude that in adherent HM, IL-1 production is potentiated and not inhibited by prostaglandins or agents that elevate cellular cAMP.

PubMed Disclaimer

Similar articles

Cited by

References

    1. J Immunol Methods. 1985 Nov 28;84(1-2):85-94 - PubMed
    1. J Clin Invest. 1979 Nov;64(5):1386-92 - PubMed
    1. J Biol Chem. 1986 Jul 5;261(19):8624-32 - PubMed
    1. J Exp Med. 1972 Jul 1;136(1):128-42 - PubMed
    1. J Biol Chem. 1982 Oct 25;257(20):12148-52 - PubMed

MeSH terms